Albany Molecular Research, Inc. is a contract research and manufacturing company. The Company operates through Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), Drug Product (DP) and Fine Chemicals (FC) segments. The DDS segment includes activities, such as drug lead discovery, optimization, drug development and small scale commercial manufacturing. The API segment includes pilot to commercial scale manufacturing of active pharmaceutical ingredients and intermediates. The DP segment includes pre-formulation, formulation and process development through commercial scale production of complex liquid-filled and lyophilized sterile injectable products and ophthalmic formulations. The FC segment includes lab to commercial scale synthesis of reagents and diverse compounds. It supplies a range of services and technologies supporting the discovery and development of pharmaceutical products, the manufacturing of API and drug product for new and generic drugs.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolNASDAQ:AMRI
CUSIPN/A
Phone+1-518-4640279
Debt
Debt-to-Equity Ratio0.62
Current Ratio0.68
Quick Ratio0.37
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-5.93%
Return on Equity-13.39%
Return on Assets-3.42%
Miscellaneous
Employees3,085
Outstanding Shares43,120,000
Market Cap$937.41 million
Albany Molecular Research (NASDAQ:AMRI) Frequently Asked Questions
What is Albany Molecular Research's stock symbol?
Albany Molecular Research trades on the NASDAQ under the ticker symbol "AMRI."
How were Albany Molecular Research's earnings last quarter?
Albany Molecular Research, Inc. (NASDAQ:AMRI) released its quarterly earnings results on Tuesday, May, 10th. The biotechnology company reported $0.07 EPS for the quarter, missing the Thomson Reuters' consensus estimate of $0.21 by $0.14. The biotechnology company earned $102.80 million during the quarter, compared to analyst estimates of $107.20 million. Albany Molecular Research had a negative return on equity of 13.39% and a negative net margin of 5.93%. View Albany Molecular Research's Earnings History.
Who are Albany Molecular Research's key executives?
Albany Molecular Research's management team includes the folowing people:
- William S. Marth, President, Chief Executive Officer, Director
- Felicia Ladin, Chief Financial Officer, Senior Vice President, Treasurer
- Lori M. Henderson Esq., Senior Vice President, General Counsel, Secretary
- Christopher M Conway, Senior Vice President - Discovery and Development and Global Commercial Sales
- , Bio & Compensation -
- Milton Boyer, Senior Vice President - Drug Product Manufacturing
- , Bio & Compensation -
- Steven R. Hagen Ph.D., Senior Vice President - Manufacturing and Pharmaceuticals
- George Svokos, Chief Commercial Officer and Senior Vice President, API
- Jimmy Wang Ph.D., Chief Information Officer
- , Bio & Compensation -
- Thomas E. D' Ambra Ph.D., Non-Executive Chairman of the Board
- David H. Deming, Director
Has Albany Molecular Research been receiving favorable news coverage?
News coverage about AMRI stock has been trending somewhat positive on Wednesday, according to Accern Sentiment. The research firm identifies negative and positive news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Albany Molecular Research earned a coverage optimism score of 0.05 on Accern's scale. They also gave media headlines about the biotechnology company an impact score of 45.68 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future. View Recent Headlines for Albany Molecular Research.
How do I buy shares of Albany Molecular Research?
Shares of AMRI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Albany Molecular Research's stock price today?
One share of AMRI stock can currently be purchased for approximately $21.74.
How big of a company is Albany Molecular Research?
Albany Molecular Research has a market capitalization of $937.41 million. Albany Molecular Research employs 3,085 workers across the globe.
How can I contact Albany Molecular Research?
Albany Molecular Research's mailing address is 21 Corporate Cir, PO Box 15098, ALBANY, NY 12203-5154, United States. The biotechnology company can be reached via phone at +1-518-4640279.
MarketBeat Community Rating for Albany Molecular Research (NASDAQ AMRI)
MarketBeat's community ratings are surveys of what our community members think about Albany Molecular Research and other stocks. Vote "Outperform" if you believe AMRI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMRI will underperform the S&P 500 over the long term. You may vote once every thirty days.
